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Background: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a common cause of
hyponatremia in hospitalized patients and is often described in patients with small-cell carcinoma of the lung.
In this report, we described both Castleman’s disease and lymphoma coexisting in one patient with SIADH.
Case presentation: A 70-year-old Chinese woman with a history of diabetes mellitus and insulin therapy had
severe hyponatremia and gastrointestinal symptoms. Through a series of examinations, common causes such as
pulmonary carcinoma were excluded. An abdominal mass was detected by computed tomography. Although the
peripheral lymph node biopsy showed the pathological result as Castleman’s disease, the pathology of the
abdominal lymph node revealed diffuse large B-cell lymphoma. After chemotherapy, the hyponatremia was treated
during a period of follow-up.
Conclusion: This patient presented with the rare clinical condition of inappropriate antidiuretic hormone secretion
alongside Castleman’s disease and lymphoma. Asymptomatic hyponatremia may persist for some time suggesting
that clinical physicians should pay attention to the mild cases of hyponatremia. We also hypothesized that
Castleman’s disease is a condition of pre-lymphoma with both having the ability to cause SIADH. The possibility
of lymphoma as well as Castleman’s disease triggering the development of SIADH should also be taken into
consideration for conducting recurrent biopsies.
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The syndrome of inappropriate antidiuretic hormone se-
cretion (SIADH) is caused by the excessive release of
antidiuretic hormone (ADH, also known as vasopressin)
from the posterior pituitary gland [1,2] and can cause
hyponatremia in hospitalized patients with an incidence
as high as 30% [3]. SIADH is generally seen in patients
diagnosed with small-cell lung cancer (SCLC) which was
first described by Schwartz et al. in two patients with
lung cancer [4].* Correspondence: meichuqin@yahoo.com.cn
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reproduction in any medium, provided the orSIADH is not difficult to diagnose in clinic. It can be
secondary to a variety of disorders, such as medications,
malignancies, surgery, and HIV infection or be idio-
pathic [1,2]. While SCLC is the primary malignancy
causing SIADH, lymphoma can also induce this condi-
tion [5,6]. In this report, the diagnosis of Castleman’s
disease was established before we suspected SIADH was
caused by a malignancy. After extensive examinations,
we made the final diagnosis of diffuse large B-cell
lymphoma. Chemotherapy treatment was recommended
for the patient and significantly ameliorated the SIADH
symptoms.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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In October 2011, a 70-year-old Han Chinese woman with
Type 2 diabetes (T2D) was admitted to Department of
Endocrinology at the Tianjin Medical University General
Hospital for uncontrolled hyperglycemia. The patient had
a history of T2D for 21 years and received continuous
long-term insulin treatment with a dosage of about fifty
units per day. On the seventh day after admission, the pa-
tient developed symptoms of nausea and vomiting accom-
panied by left leg radiating pain without diarrhea and
fever. She did not present with headache, dizziness, dis-
turbance of consciousness, melana or hematemesis. The
medications used in the hospital are listed in Table 1. The
patient had no recent history of using diuretic agents.
Serum sodium levels decreased to 112 mmol/l and chlo-
ride levels to 81 mmol/l with an effective osmolality at
267 mOsm/kg.H2O (normal range: 280–310 mOsm/kg.
H2O). Urinary sodium increased to 85 mmol/l and chlo-
ride to 86 mmol/l with an osmolality of 257 mOsm/kg.
H2O indicating hypotonicity during normal dietary salt
intake. She was clinically normovolemic with no signs
of fluid retention. Her hepatic and renal functions were
normal with a serum creatinine of 68 (normal range:
44–115) umol/L. Fractional sodium excretion was calcu-
lated as 1.56%. Thyroid and adrenal function were mea-
sured with ACTH= 59.8 pg/mL(normal range: 0–46),
cortisol = 25.6 ug/dL(normal range: 5–25), 24-hour cor-
tisol in urine = 64.4 ug(normal range: 30–110), FT3 =
3.04 pmol/L(normal range: 3.5–6.5), FT4 = 19.76 pmol/L
(normal range: 11.5–23.5), TSH = 3.657 uIU/mL(normal
range: 0.3–5.0) and rT3 = 1.76 nmol/l (normal range:
0.43–1.15). The magnetic resonance imaging (MRI) of
her pituitary gland showed herniation of the suprasellar
cistern. Based on the MRI result, our first diagnosis was
hypopituitarism, which was treated with intravenous
hydrocortisone at 50 mg/day. Both the serum sodium and
serum chloride increased from 112 to 116 mmol/l and from
81 to 84 mmol/l, respectively, on the following day.
After further inquiry, the patient informed us of a past
history of Mucosal-associated lymphoid tissue lymphoma
(MALT) which had not received further treatment. We
also discovered that she was last hospitalized on March
2011 for uncontrolled hyperglycemia without symptoms of
nausea and vomiting. Nevertheless, hyponatremia had been
noticed with serum sodium of 131 mmol/L and serumTable 1 Medications used in the current hospitalization
Medicine Dose Times
Voglibose 0.3 mg 3
Glimepiride 4 mg Once in the morning
Glimepiride 2 mg Once in the evening
Insulin Aspart 30 28 IU 2
Irbesartan 150 mg 1chloride of 95 mmol/l. Urinary investigation showed in-
creased levels of sodium (90 mmol/l) and chloride
(83 mmol/l) without corresponding osmolality data. Her
renal function was normal with a serum creatinine of 63
umol/L. This information led us to believe that SIADH
caused the patient’s hyponatremia. Three days after
restricting fluid intake to 1000 ml/day, the serum sodium
rose to 128 mmol/L from 116 mmol/L. Ten days later, the
patient’s serum sodium levels increased to 142 mmol/l, and
the symptoms of nausea and vomiting disappeared.
Since the patient had a past history of MALT, we
performed a gastric endoscopy, which indicated the ab-
sence of lymphoma. Additionally, the serology result was
negative for purified protein derivative (PPD), and the
serum and urine protein electrophoresis were also nega-
tive for monoclonal gammopathy. Additional laboratory
findings were listed in Table 2. A negative chest computed
tomography (CT) scan excluded the possibility of SCLC as
the cause of SIADH in this patient. However, we noticed
that the patient had obvious pain in the left leg, abdo-
minal distension, and skin itching on a clinical exam and
further discovered that her abdomen circumference had
increased significantly in the last six months. An abdo-
minal CT scan showed that a mass measuring approxi-
mately 49 mm*70 mm*90 mm was located on front
lumbar vertebra 1–4 and the surrounding abdominal
aorta. A subsequent abdominal enhancement CT revealed
that the mass might be lymphoma (Figure 1). As the patho-
logical result was critical for her diagnosis, we conducted a
left inguinal lymph node puncture showing no abnormal
lymphocytes. Consequently, a whole left inguinal (2 × 1 ×
0.5 cm) lymph node was resected. The pathological morph-
ology revealed that the lymph node structure was replaced
with substantial amounts of lymphoid tissue and fibrosis.
Thus, the diagnosis of Castleman’s disease was established
according to the pathological exam (Figure 2A, B, C).
Although hyponatremia was corrected, her hemog-
lobulin levels decreased from 109 g/L to 96 g/L. With her
consent, we conducted a biopsy of the enlarged abdominal
lymph node by using a celioscope. The pathological exam
disclosed diffuse large B-cell lymphoma with an anaplastic
subtype (Figure 3A, B).
After the diagnosis of lymphoma was established, the
patient was transferred to the Department of Hematology
for further treatment. For the etiology treatment of B-cell
lymphoma, the chemotherapy of cyclophosphamide, hy-
droxydaunorubicin, oncovin and prednisone (CHOP) with
rituximab (a monoclonal antibody against the protein
CD20) was administered. The patient’s serum sodium
level stabilized without fluid restriction.
Discussion
In this case, the hyponatremia had existed for a long
time and failed to gain proper attention until serious





FBG 12.5 3.9-6.1 mmol/L
24-h proteinuria 124.2 0-150 mg
Blood urea nitrogen 4 1.7-8.3 mmo/L
Serum uric acid 144 140-414 μmol/L
Serum creatinine 68 44-115 μmol/L
Ccr 86.8 80-120 ml/min
ACTH 59.8 0-46 pg/mL
Cortisol 25.6 5-25 μg/dL
24-hour cortisol in urine 64.4 30-110 ug
FT3 3.04 3.5-6.5 pmol/L
FT4 19.76 11.5-23.5 pmol/L
TSH 3.657 0.3-5.0 μIU/mL
rT3 1.76 0.43-1.15 nmol/l
ESR 21 0-20 mm/h
Lactic acid dehydrogenase 186 94-250 U/L
ß2-microglobulin 2.04 0.8-2.0 mg/L
Antinuclear antibody Negative
Immunoglobulin G 811 751-1560 mg/dl
Immunoglobulin A 64.8 82-453 mg/dl
Immunoglobulin M 48.1 46-304 mg/dl
C3 88.9 79-152 mg/dl
C4 17.10. 16-38 mg/dl
C-reactive protein 1.07 <0.80 mg/dl
Circulating immunologic complex 4.2 <13 U/ml
Immunoglobulin E <5.00 <165 IU/ml
Alpha Fetoprotein 4.42 0-20 ng/ml
Ferritin 272.87 4.6-204 ng/ml
Carcinoembryonic antigen 1.42 0-5 ng/ml
Carbohydrate antigen19-9 <0.60 0-37 U/ml
Carbohydrate antigen 242 0.05 0-20 U/ml
Carbohydrate antigen 153 16.3 0-30 U/ml
HIV Negative
Figure 1 CT scan of abdomen showing a mass. Axial contrast-
enhanced CT image shows a large lobulated irregular mass with
inhomogenous enhancement that is encasing and anteriorly
displacing the abdominal aorta.
Zhu et al. BMC Endocrine Disorders 2013, 13:19 Page 3 of 5
http://www.biomedcentral.com/1472-6823/13/19clinical manifestations developed. Her past history of
MALT as well as the success of fluid restriction and failure
of hydrocortisone infusion suggested the possibility of
hyponatremia caused by SIADH. One limitation of our
investigation was the failure to measure urine uric acid
and urea levels. Fractional uric acid excretion (FE-UA) has
been demonstrated as a useful criterion in the diagnosis of
SIADH particularly when attempting to differentiate
between SIADH and hypovolaemic hyponatremia [7].
The main therapeutic issue in SIADH is fluid excess,
and hyponatremia is dilutional in essence. Fluid restrictionis the primary treatment option for SIADH. The
vasopressin V2 receptor antagonist is effective for
assisting the SIADH treatment [8]. Urea administration
could be used in patients with chronic SIADH but also in
acute SIADH like in critically ill patients [9].
Once a diagnosis of SIADH is established, determining
its cause is most important. Castleman’s disease is char-
acterized by non-cancerous growths that may develop in
the lymph node tissue throughout the body [10]. Lesions
often occur in the chest, abdomen, or neck, where the
abnormal enlargement of lymph nodes could usually be
found. Although SIADH is reported to be associated
with Castleman’s disease [11], the possibility of general
lymphoma in this case could not be excluded. Several
major points supported this conclusion including: (1)
past history of MALT; (2) occurrence of itching
(characteristic symptom of lymphoma); (3) CT scan fin-
dings suggested lymphoma; and (4) the manifestation of
progressive anemia. Moreover, the patient had a long his-
tory of T2D treated with insulin. Recent studies suggest
that insulin treatment may be associated with an higher
risk of the developing certain types cancers including
lymphoma [12].
Although Castleman’s disease is inherently a non-
neoplastic process, an association with concurrent or
subsequent lymphoma has been well described [13]. The
hyaline-vascular type of Castleman’s disease which con-
tains numerous lymphoid follicles should be differentiated
from Hodgkin lymphoma and low-grade B-cell lymphomas
[14]. Several B-cell lymphomas with prominent atrophic
germinal centers and hyaline vascular penetration inclu-
ding follicular lymphoma, mantle cell lymphoma, and
Figure 2 The pathological exam suggests Castleman’s disease.
The gross examination of the inguenal lymph node biopsy
specimen shows a fairly well-encapsulated, soft tan lesion with a
largest dimension of 1.2 cm. Microscopy reveals areas of hyaline-
vascular Castleman’s disease-like pattern. The majority of the
lymphoid follicles had atrophic or regressive germinal centers, and
some of them are penetrated by capillaries. There was concentric
layering of lymphocytes in an onion-skin appearance and one or
more penetrating blood vessels. The interfollicular stroma was also
prominent with numerous hyperplastic vessels of the post-capillary
venule type and plump endothelial lining. (A) concentric layering of
lymphocytes in an onion-skin appearance; (B) a “lollipop”
appearance; (C) two atrophic germinal centers within a single
mantle zone.
Figure 3 An abdominal lymph node biopsy suggests the
diagnosis of diffuse large-B cell lymphoma, anaplastic subtype.
(A) At low magnification, the normal nodal architecture was totally
effaced and the node was diffusely infiltrated by a population of
large atypical lymphocytes with a highly characteristic morphology.
Extensive infiltration of the perinodal adipose tissue was observed as
well. (Haematoxylin and eosin). (B) High magnification show that
nuclei were round to oval with fine chromatin; Extensive areas of
coagulative necrosis and karyorrhectic nuclei were present. Reed-
Sternberg–like forms and giant cells are also prominent and
conspicuous nucleoli are seen in these cells. Eosinophilic region was
seen near the nucleus, probably representing a prominent
Golgi apparatus.
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as Castleman’s disease due to the similar clinicopatho-
logic features [15]. Furthermore, multicentric Castleman’s
disease could show similar FDG PET/CT appearance
mimicking lymphoma, which reveals that Castleman’s
disease and lymphoma exhibit similar functions [16]. After
consulting the literaure and examining the presentation of
SIADH caused by both diseases, we hypothesized that
Castleman’s disease can develop into lymphoma, and a va-
riety of pathological lymphomas may result in the
Zhu et al. BMC Endocrine Disorders 2013, 13:19 Page 5 of 5
http://www.biomedcentral.com/1472-6823/13/19development of SIADH [6,17]. One possible mechanism is
the effect of hypercytokinemia. Some cytokines, such as
interleukin (IL)-2, IL-6, IL-1β, and tumor necrosis factor
(TNF)-α, have been reported to stimulate parvicellular
and magnocellular neurons to secrete more ADH thus
causing SIADH [18,19].
In our case, three separate biopsies showed differing
results suggesting that this procedure is so imperative for
certain conditions that several biopsies may be needed
for a final diagnosis.
Conclusion
This report describes a rare case, in which an older woman
had both Castleman’s disease and lymphoma coexisting
with SIADH. We wish to highlight the following key
points: First, lymphoma as well as Castleman’s disease,
though uncommon, is an important cause of SIADH, and
mild hyponatemia should get proper attention by clinical
endocrinologists. Second, repeated lymph node biopsy may
be crucial for the etiological diagnosis of SIADH.
Consent
Written informed consent was obtained from the patient
for publication of this case report and the accompanying
images. A copy of the written consent is available upon
request for review by the Journal Editor.
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